MNG1143
—
Clinical attributes
From the source cohort, normalized into canonical keys plus the project's native columns.
- cancer_type
- —
- cancer_type_detailed
- —
- subtype
- —
GSVA pathway preview (50 Hallmark scores)
Top 10 most elevated and top 10 most suppressed Hallmark pathways for this sample.
Top 10 elevated
- PANCREAS_BETA_CELLS+0.534
- ANGIOGENESIS+0.363
- KRAS_SIGNALING_DN+0.317
- EPITHELIAL_MESENCHYMAL_TRANSITION+0.313
- SPERMATOGENESIS+0.311
- COAGULATION+0.302
- HYPOXIA+0.191
- ESTROGEN_RESPONSE_LATE+0.180
- ESTROGEN_RESPONSE_EARLY+0.173
- KRAS_SIGNALING_UP+0.149
Top 10 suppressed
- MYC_TARGETS_V2-0.603
- OXIDATIVE_PHOSPHORYLATION-0.489
- UNFOLDED_PROTEIN_RESPONSE-0.466
- MYC_TARGETS_V1-0.464
- WNT_BETA_CATENIN_SIGNALING-0.435
- DNA_REPAIR-0.432
- REACTIVE_OXYGEN_SPECIES_PATHWAY-0.410
- MITOTIC_SPINDLE-0.407
- ADIPOGENESIS-0.398
- PROTEIN_SECRETION-0.386
Patient twins — nearest pathway neighbors
10 samples closest to this one in 50-dim pathway space, drawn from the Pathway Atlas. Cosine similarity = 1 means identical pathway state.
9 twins match this tumor's tissue · 1 come from a different tissue of origin
| # | Sample | Cancer type | Subtype | cos similarity |
|---|---|---|---|---|
| 1 | MNG1123 | — | — | 0.917 |
| 2 | R415 | — | — | 0.916 |
| 3 | MNG204 | — | — | 0.906 |
| 4 | SRR1516038 | — | — | 0.901 |
| 5 | MNG860 | — | — | 0.901 |
| 6 | SRR1434138 | GTEX | — | 0.900 |
| 7 | MNG1158 | — | — | 0.900 |
| 8 | MNG1152 | — | — | 0.898 |
| 9 | MNG325 | — | — | 0.892 |
| 10 | MNG613 | — | — | 0.891 |
Per-pathway drug coverage
For each elevated pathway in this tumor, the best-reversing drug across the catalog. Uncovered pathways = unmet need at pathway level for this one patient.
0 of 15 elevated pathways have at least one drug that meaningfully reverses them.
| Pathway (elevated) | tumor score | Best drug | reversal magnitude |
|---|---|---|---|
| PANCREAS_BETA_CELLS | 0.534 | Cobimetinib | — uncovered |
| ANGIOGENESIS | 0.363 | Remibrutinib | — uncovered |
| KRAS_SIGNALING_DN | 0.317 | Remibrutinib | — uncovered |
| EPITHELIAL_MESENCHYMAL_TRANSITION | 0.313 | Inavolisib | — uncovered |
| SPERMATOGENESIS | 0.311 | Inavolisib | — uncovered |
| COAGULATION | 0.302 | Binimetinib | — uncovered |
| HYPOXIA | 0.191 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_LATE | 0.180 | Idelalisib | — uncovered |
| ESTROGEN_RESPONSE_EARLY | 0.173 | Inavolisib | — uncovered |
| KRAS_SIGNALING_UP | 0.149 | Inavolisib | — uncovered |
| HEDGEHOG_SIGNALING | 0.112 | Inavolisib | — uncovered |
| MYOGENESIS | 0.088 | Inavolisib | — uncovered |
| APICAL_SURFACE | 0.080 | Temsirolimus | — uncovered |
| XENOBIOTIC_METABOLISM | 0.028 | Inavolisib | — uncovered |
| BILE_ACID_METABOLISM | 0.027 | Inavolisib | — uncovered |